Team
health

Revised Geneva Score Calculator

The Revised Geneva Score is a validated clinical risk stratification tool designed to estimate the probability of pulmonary embolism in acute care environments. Emergency physicians, hospitalists, and acute care providers use it to rapidly quantify PE likelihood based on patient demographics, medical history, vital signs, and physical examination findings. The score guides diagnostic urgency and helps standardise risk assessment across different clinical settings.

Last updated:

Creators Małgorzata Koperska, MD
673 people find this calculator helpful

Understanding Pulmonary Embolism and Risk Stratification

Pulmonary embolism occurs when a blood clot lodges in the pulmonary arterial circulation, typically originating from deep veins in the lower extremities. The resulting pulmonary arterial obstruction impairs gas exchange and increases right ventricular afterload, potentially causing haemodynamic collapse and sudden death. Approximately 80% of PE cases are attributed to thromboembolism from the legs, whilst other sources include pelvic veins, right heart chambers, or upper extremity vessels.

Diagnosis of PE remains clinically challenging because presentation varies widely—from incidental findings on imaging to fulminant cardiovascular collapse. Symptoms overlap substantially with other acute cardiopulmonary conditions, making clinical gestalt unreliable. Systematic risk scoring, combined with validated biomarkers like D-dimer and imaging with computed tomography pulmonary angiography (CTPA), forms the modern diagnostic algorithm.

The Revised Geneva Score simplifies risk assessment compared to its 2006 predecessor by eliminating invasive measurements whilst maintaining diagnostic accuracy. It assigns points for eight discrete variables, generating a total that correlates with PE probability across clinical practice.

Revised Geneva Score Calculation

The score sums eight clinical and demographic parameters, each contributing 0–3 points depending on specific thresholds. Points are assigned for age above 65 years, active malignancy, recent surgery or fracture, prior venous thromboembolism, haemoptysis, and abnormal vital signs or physical examination findings:

Revised Geneva Score = Age + DVT/PE History + Surgery/Fracture +

Malignancy + Unilateral Leg Pain + Haemoptysis +

Heart Rate + Unilateral Leg Oedema/Tenderness

  • Age — 1 point if 60–64 years; 2 points if ≥65 years; 0 points if <60 years
  • DVT/PE History — 3 points for documented prior deep vein thrombosis or pulmonary embolism
  • Surgery/Fracture — 2 points for lower limb fracture or surgery under general anaesthesia within the past month
  • Malignancy — 2 points for active cancer requiring treatment or diagnosed within the past year
  • Unilateral Leg Pain — 3 points for swelling and pain in one lower extremity without alternative diagnosis
  • Haemoptysis — 2 points for coughing up blood
  • Heart Rate — 1 point if 75–94 beats/minute; 2 points if ≥95 beats/minute
  • Unilateral Leg Oedema/Tenderness — 2 points for unilateral swelling or pain on deep palpation during compression ultrasound

Clinical Interpretation and PE Probability

Score thresholds correlate with PE prevalence in validation cohorts. A score of 0–3 points indicates low probability (approximately 5–8%); 4–6 points suggests intermediate probability (20–30%); and ≥7 points reflects high probability (40–50% or greater). However, these figures vary by population studied and reflect pre-test probability only.

Clinical decision-making should never rely solely on the score. A low Geneva Score does not exclude PE in high-clinical-suspicion scenarios; conversely, a high score with low clinical suspicion warrants selective imaging rather than automatic CTPA. The score is most useful as a structured framework for standardising risk discussion and guiding the threshold for further investigation.

When PE probability is intermediate, D-dimer testing becomes particularly valuable. A negative high-sensitivity D-dimer substantially lowers PE likelihood and may allow safe deferral of imaging in selected patients. Conversely, elevated D-dimer in the setting of high Geneva Score warrants urgent CTPA or ventilation–perfusion imaging depending on renal function and contrast contraindications.

Practical Considerations and Common Pitfalls

Misapplication of risk scores or over-reliance on numerical results can delay diagnosis or trigger unnecessary testing.

  1. Do Not Anchor on Score Alone — A single risk score never replaces clinical judgment. Patients with compelling symptoms, signs, or risk factors warrant investigation regardless of a "reassuring" Geneva Score. Conversely, asymptomatic screening in low-risk patients—such as routine pre-operative assessment—generates false positives that expose patients to unnecessary anticoagulation.
  2. Recognise Score Limitations in Pregnancy and Malignancy — Pregnant patients and those with active cancer have substantially elevated baseline PE risk that generic scoring systems underestimate. Pregnancy increases venous stasis, triggers hypercoagulability, and compresses pelvic veins—all amplifying thromboembolism risk. Cancer patients often receive central lines, chemotherapy, or prolonged immobility, compounding risk. Use the Geneva Score as one input, not the sole guide, in these populations.
  3. Heart Rate Interpretation Requires Context — Tachycardia reflects many conditions: sepsis, dehydration, pain, anxiety, cardiac disease, or hypoxia. A heart rate ≥95 beats/minute contributes 2 points but is non-specific. In a hypotensive patient with tachycardia and acute dyspnoea, assume PE until proven otherwise, even if other score components are low.
  4. Remember the Absence of Lower Limb Signs — Absence of unilateral leg pain or swelling does not exclude leg DVT—the source of most PEs. Proximal deep vein thrombosis can be asymptomatic or present with subtle swelling. If PE probability remains high clinically, consider lower limb ultrasound regardless of physical examination findings.

VTE Prophylaxis and Risk Reduction Strategies

Once PE risk is stratified, management focuses on preventing new clots whilst anticoagulating existing ones. Mechanical prophylaxis—graduated compression stockings or intermittent pneumatic compression devices—reduces VTE recurrence in immobile patients, particularly those post-operatively or in intensive care.

Pharmacologic prophylaxis includes anticoagulants: unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), fondaparinux, and novel oral anticoagulants (DOACs). Choice depends on renal function, bleeding risk, reversibility requirements, and clinical context. UFH offers rapid reversibility and minimal renal clearance, making it ideal for peri-operative high-risk patients. LMWH and fondaparinux suit intermediate-risk patients with normal renal function.

Inferior vena cava (IVC) filters prevent PE in patients with documented DVT who cannot tolerate anticoagulation due to active bleeding, thrombocytopenia, or haemorrhagic stroke. Retrievable filters allow removal once the contraindication resolves, reducing filter-related complications such as recurrent DVT or filter thrombosis.

Frequently Asked Questions

What is the difference between the Revised Geneva Score and the original Geneva Score?

The original 2006 Geneva Score included clinical items alongside objective measures such as blood gas analysis and chest radiograph interpretation, making it more complex and dependent on laboratory availability. The Revised version, introduced to streamline assessment, eliminates blood gas and imaging requirements, relying instead on bedside evaluation of age, vital signs, and clinical findings. This simplification maintains diagnostic accuracy whilst improving ease of application in emergency and acute care settings without sacrificing reliability.

Can the Revised Geneva Score be used to exclude pulmonary embolism?

No. A low score reduces PE likelihood but does not exclude it with sufficient confidence to forgo further investigation in clinically suspicious patients. The score generates a probability estimate; clinical gestalt, presenting symptoms, and risk factors must guide the decision to pursue imaging. High-sensitivity D-dimer testing combined with a low Geneva Score can safely exclude PE in very-low-risk cohorts, but this strategy requires institutional validation and careful patient selection.

How does the Revised Geneva Score compare to the Wells Score?

Both are validated diagnostic aids, but they weight variables differently. The Wells Score emphasises clinical impression and PE likelihood, whereas the Revised Geneva Score uses more objective parameters. The Wells Score tends to categorise more patients as intermediate-risk, potentially increasing imaging volume. Neither is uniformly superior; choice depends on clinician familiarity, institutional protocols, and the specific patient population being evaluated.

What should I do if my patient has a high Geneva Score but low clinical suspicion for PE?

Elevated Geneva Scores in low-suspicion patients often reflect common acute illnesses—pneumonia, sepsis, or decompensated heart failure—rather than PE. Ensure your clinical suspicion assessment accounts for risk factors, symptom onset, and alternative diagnoses. If clinical suspicion remains low, selective D-dimer testing or imaging may be withheld, but document your reasoning. Conversely, if multiple risk factors cluster or you retain concern, proceed to imaging rather than anchoring entirely on clinical intuition.

Is the Revised Geneva Score validated in pregnant patients or those with cancer?

The score was derived and validated in general acute care populations, not specifically in pregnant or oncologic patients. Both groups have substantially elevated baseline PE risk due to hypercoagulability, immobility, and vascular injury. When applying the score to pregnant or cancer patients, use it as one component of assessment rather than the primary decision tool. Lower thresholds for imaging are warranted in these populations given their inherently higher PE prevalence.

How should I interpret a score of 4–6 points (intermediate probability)?

Intermediate-probability scores indicate PE prevalence of roughly 20–30% in cohorts used for validation. At this probability level, D-dimer testing becomes particularly useful: a negative high-sensitivity D-dimer substantially reduces post-test PE probability, potentially obviating imaging in some patients, whilst a positive D-dimer raises probability enough to justify CTPA. The exact thresholds and imaging strategy should follow your institution's diagnostic algorithms and local guidelines for PE evaluation.

More health calculators (see all)

PERC Calculator STOP-BANG Calculator Weight Gain Calculator Padua Score Calculator IVIG Dose Calculator Glycemic Index Calculator Implantation Calculator BMR Calculator